At present, diseases such as obesity, type Ⅱ diabetes and cancer have brought serious health
problems, which are closely related to mTOR pathway. 70 kDa ribosomal protein S6 kinase (p70S6K),
as a significant downstream effector of mTOR, mediates protein synthesis, RNA processing, glucose
homeostasis, cell growth and apoptosis. Inhibiting the function of p70S6K can reduce the risk of obesity
which helps to treat dyslipidemia, enhance insulin sensitivity, and extend the life span of mammals.
Therefore, p70S6K has become a potential target for the treatment of these diseases. So far, except for
the first p70S6K specific inhibitor PF-4708671 developed by Pfizer and LY2584702 developed by
Lilai, all of them are in preclinical research. This paper briefly introduces the general situation of
p70S6K and reviews their inhibitors in recent years, which are mainly classified into two categories:
natural compounds and synthetic compounds. In particular, their inhibitory activities, structure-activity
relationships (SARs) and mechanisms are highlighted.